Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. GLP-1 and obesity: International Journal of Molecular Sciences (2019)
Varios medicamentos se prescriben por separado para ambas afecciones, mientras que unas pocas frmulas tienen resultados positivos en ambas afecciones
Control Release 290, 1127
If you are pregnant or planning to become pregnant, semaglutide should be discontinued
The highest dose led to the most weight loss12 percent on average, or about 27 pounds, compared to 2 pounds with the placebo
Never throw used needles in the regular trash